A Phase 1b/2 Study of AMG 655 in Combination With Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 29 May 2015

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Conatumumab (Primary) ; Doxorubicin
Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma
Focus Therapeutic Use
Sponsors Amgen

10 Jan 2012 Results published in the European Journal of Cancer.
26 Nov 2008 Planned end date changed from 1 Mar 2012 to 1 May 2012, according to ClinicalTrials.gov.
26 Nov 2008 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com